Clinical Trial Update: HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

HP-211 is being evaluated in a Phase 2 safety and proof-of-concept dose-ranging study for Type 2 diabetes mellitus. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• HP-211

Snippet

Sponsor: Housey Healthcare ULC | Conditions: Type 2 Diabetes | Phase 2 | Status: RECRUITING